Operating through 60 Company-operated treatment centers, Greenbrook is a leading provider of TMS, an FDA-cleared, non-invasive therapy for the treatmentof Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook TMS has provided more than 200,000 TMS treatments to over 5,700 patients struggling with depression.
For copies of our financial statements and other continuous disclosure filings, please see the Greenbrook TMS profile at SEDAR (System for Electronic Document Analysis and Retrieval) by clicking the link below.
Bill Leonard, President and Chief Executive Officer and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on March 28, 2019 to discuss the financial results for the quarter and year end.
For more information or to listen to the call via webcast, please visit:
The conference call replay will be available from 1:00 p.m. (Eastern Time) on March 28, 2019, until 23:59 p.m. (Eastern Time) on April 29, 2019.
February 26, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS
January 9, 2018 – Toronto, ON –
GREENBROOK TMS ANNOUNCES EXPANSION INTO TAMPA-ST. PETERSBURG FLORIDA
December 28, 2018 – Toronto, ON –
GREENBROOK TMS ANNOUNCES EXPANSION INTO CLEVELAND OHIO
November 12, 2018 – Toronto, ON –
GREENBROOK TMS CONTINUES SUCCESSFUL EXECUTION OF GROWTH STRATEGY AND REPORTS THIRD QUARTER FINANCIAL RESULTS